SCHEMBL13079656

SCHEMBL13079656

COc1c(Cl)c(/C=C(\Br)C(=O)O)c(OC)c2ccccc12

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.39
ALDH1A1 P00352 3/20 0.39
MAPK1 P28482 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
IDO1 P14902 1/20 0.37
APEX1 P27695 2/20 0.35
CCR2 P41597 1/20 0.34
HSD17B10 Q99714 1/20 0.34
CYP1A1 P04798 1/20 0.34
CYP1B1 Q16678 1/20 0.34
SLC2A1 P11166 2/20 0.34
MCL1 Q07820 2/20 0.33
POLB P06746 2/20 0.33
BCL2A1 Q16548 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
AKR1C3 P42330 1/20 0.33
PTGER4 P35408 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3750251 0.87 AKR1C3 (0.45) KDM4EALDH1A1MAPK1SMN1; SMN2CYP1A2
SCHEMBL3750250 0.87 AKR1C3 (0.45) KDM4EALDH1A1MAPK1SMN1; SMN2CYP1A2
SCHEMBL3754493 0.87 AKR1C3 (0.45) KDM4EALDH1A1MAPK1SMN1; SMN2CYP1A2
SCHEMBL13080081 0.81 KDM4E (0.37) KDM4EALDH1A1MAPK1SMN1; SMN2CYP1A2
SCHEMBL13080079 0.81 KDM4E (0.37) KDM4EALDH1A1MAPK1SMN1; SMN2CYP1A2
SCHEMBL3751223 0.80 APEX1 (0.40) KDM4EALDH1A1MAPK1SMN1; SMN2CYP1A2
SCHEMBL3751227 0.80 APEX1 (0.40) KDM4EALDH1A1MAPK1SMN1; SMN2CYP1A2
SCHEMBL13080052 0.80 APEX1 (0.40) KDM4EALDH1A1MAPK1SMN1; SMN2CYP1A2
SCHEMBL3806856 0.79 KDM4E (0.35) KDM4EALDH1A1MAPK1SMN1; SMN2CYP1A2
SCHEMBL13894727 0.78 APEX1 (0.42) KDM4EALDH1A1MAPK1SMN1; SMN2CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100297113-A1 QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF PURDUE RESEARCH FOUNDATION 2010-11-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100297113-A1 QUINONE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF APEX1, NQO1, REV1 KDM4E 2642/4885ALDH1A1 210/4885MAPK1 2142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.